Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Genetic testing in inherited endocrine disorders: joint position paper of the European reference network on rare endocrine conditions (Endo-ERN)

Research output: Contribution to journalReviewpeer-review

Harvard

Eggermann, T, Elbracht, M, Kurth, I, Juul, A, Johannsen, TH, Netchine, I, Mastorakos, G, Johannsson, G, Musholt, TJ, Zenker, M, Prawitt, D, Pereira, AM, Hiort, O & European Reference Network on Rare Endocrine Conditions (ENDO-ERN 2020, 'Genetic testing in inherited endocrine disorders: joint position paper of the European reference network on rare endocrine conditions (Endo-ERN)', Orphanet Journal of Rare Diseases, vol. 15, no. 1, pp. 144. https://doi.org/10.1186/s13023-020-01420-w

APA

Eggermann, T., Elbracht, M., Kurth, I., Juul, A., Johannsen, T. H., Netchine, I., Mastorakos, G., Johannsson, G., Musholt, T. J., Zenker, M., Prawitt, D., Pereira, A. M., Hiort, O., & European Reference Network on Rare Endocrine Conditions (ENDO-ERN (2020). Genetic testing in inherited endocrine disorders: joint position paper of the European reference network on rare endocrine conditions (Endo-ERN). Orphanet Journal of Rare Diseases, 15(1), 144. https://doi.org/10.1186/s13023-020-01420-w

CBE

Eggermann T, Elbracht M, Kurth I, Juul A, Johannsen TH, Netchine I, Mastorakos G, Johannsson G, Musholt TJ, Zenker M, Prawitt D, Pereira AM, Hiort O, European Reference Network on Rare Endocrine Conditions (ENDO-ERN. 2020. Genetic testing in inherited endocrine disorders: joint position paper of the European reference network on rare endocrine conditions (Endo-ERN). Orphanet Journal of Rare Diseases. 15(1):144. https://doi.org/10.1186/s13023-020-01420-w

MLA

Vancouver

Author

Eggermann, Thomas ; Elbracht, Miriam ; Kurth, Ingo ; Juul, Anders ; Johannsen, Trine Holm ; Netchine, Irène ; Mastorakos, George ; Johannsson, Gudmundur ; Musholt, Thomas J ; Zenker, Martin ; Prawitt, Dirk ; Pereira, Alberto M ; Hiort, Olaf ; European Reference Network on Rare Endocrine Conditions (ENDO-ERN. / Genetic testing in inherited endocrine disorders : joint position paper of the European reference network on rare endocrine conditions (Endo-ERN). In: Orphanet Journal of Rare Diseases. 2020 ; Vol. 15, No. 1. pp. 144.

Bibtex

@article{79dc550815ba40d2935e8b1da3790392,
title = "Genetic testing in inherited endocrine disorders: joint position paper of the European reference network on rare endocrine conditions (Endo-ERN)",
abstract = "BACKGROUND: With the development of molecular high-throughput assays (i.e. next generation sequencing), the knowledge on the contribution of genetic and epigenetic alterations to the etiology of inherited endocrine disorders has massively expanded. However, the rapid implementation of these new molecular tools in the diagnostic settings makes the interpretation of diagnostic data increasingly complex.MAIN BODY: This joint paper of the ENDO-ERN members aims to overview chances, challenges, limitations and relevance of comprehensive genetic diagnostic testing in rare endocrine conditions in order to achieve an early molecular diagnosis. This early diagnosis of a genetically based endocrine disorder contributes to a precise management and helps the patients and their families in their self-determined planning of life. Furthermore, the identification of a causative (epi)genetic alteration allows an accurate prognosis of recurrence risks for family planning as the basis of genetic counselling. Asymptomatic carriers of pathogenic variants can be identified, and prenatal testing might be offered, where appropriate.CONCLUSIONS: The decision on genetic testing in the diagnostic workup of endocrine disorders should be based on their appropriateness to reliably detect the disease-causing and -modifying mutation, their informational value, and cost-effectiveness. The future assessment of data from different omic approaches should be embedded in interdisciplinary discussions using all available clinical and molecular data.",
author = "Thomas Eggermann and Miriam Elbracht and Ingo Kurth and Anders Juul and Johannsen, {Trine Holm} and Ir{\`e}ne Netchine and George Mastorakos and Gudmundur Johannsson and Musholt, {Thomas J} and Martin Zenker and Dirk Prawitt and Pereira, {Alberto M} and Olaf Hiort and {European Reference Network on Rare Endocrine Conditions (ENDO-ERN}",
year = "2020",
month = jun,
day = "8",
doi = "10.1186/s13023-020-01420-w",
language = "English",
volume = "15",
pages = "144",
journal = "Orphanet Journal of Rare Diseases",
issn = "1750-1172",
publisher = "BioMed Central Ltd",
number = "1",

}

RIS

TY - JOUR

T1 - Genetic testing in inherited endocrine disorders

T2 - joint position paper of the European reference network on rare endocrine conditions (Endo-ERN)

AU - Eggermann, Thomas

AU - Elbracht, Miriam

AU - Kurth, Ingo

AU - Juul, Anders

AU - Johannsen, Trine Holm

AU - Netchine, Irène

AU - Mastorakos, George

AU - Johannsson, Gudmundur

AU - Musholt, Thomas J

AU - Zenker, Martin

AU - Prawitt, Dirk

AU - Pereira, Alberto M

AU - Hiort, Olaf

AU - European Reference Network on Rare Endocrine Conditions (ENDO-ERN

PY - 2020/6/8

Y1 - 2020/6/8

N2 - BACKGROUND: With the development of molecular high-throughput assays (i.e. next generation sequencing), the knowledge on the contribution of genetic and epigenetic alterations to the etiology of inherited endocrine disorders has massively expanded. However, the rapid implementation of these new molecular tools in the diagnostic settings makes the interpretation of diagnostic data increasingly complex.MAIN BODY: This joint paper of the ENDO-ERN members aims to overview chances, challenges, limitations and relevance of comprehensive genetic diagnostic testing in rare endocrine conditions in order to achieve an early molecular diagnosis. This early diagnosis of a genetically based endocrine disorder contributes to a precise management and helps the patients and their families in their self-determined planning of life. Furthermore, the identification of a causative (epi)genetic alteration allows an accurate prognosis of recurrence risks for family planning as the basis of genetic counselling. Asymptomatic carriers of pathogenic variants can be identified, and prenatal testing might be offered, where appropriate.CONCLUSIONS: The decision on genetic testing in the diagnostic workup of endocrine disorders should be based on their appropriateness to reliably detect the disease-causing and -modifying mutation, their informational value, and cost-effectiveness. The future assessment of data from different omic approaches should be embedded in interdisciplinary discussions using all available clinical and molecular data.

AB - BACKGROUND: With the development of molecular high-throughput assays (i.e. next generation sequencing), the knowledge on the contribution of genetic and epigenetic alterations to the etiology of inherited endocrine disorders has massively expanded. However, the rapid implementation of these new molecular tools in the diagnostic settings makes the interpretation of diagnostic data increasingly complex.MAIN BODY: This joint paper of the ENDO-ERN members aims to overview chances, challenges, limitations and relevance of comprehensive genetic diagnostic testing in rare endocrine conditions in order to achieve an early molecular diagnosis. This early diagnosis of a genetically based endocrine disorder contributes to a precise management and helps the patients and their families in their self-determined planning of life. Furthermore, the identification of a causative (epi)genetic alteration allows an accurate prognosis of recurrence risks for family planning as the basis of genetic counselling. Asymptomatic carriers of pathogenic variants can be identified, and prenatal testing might be offered, where appropriate.CONCLUSIONS: The decision on genetic testing in the diagnostic workup of endocrine disorders should be based on their appropriateness to reliably detect the disease-causing and -modifying mutation, their informational value, and cost-effectiveness. The future assessment of data from different omic approaches should be embedded in interdisciplinary discussions using all available clinical and molecular data.

U2 - 10.1186/s13023-020-01420-w

DO - 10.1186/s13023-020-01420-w

M3 - Review

C2 - 32513286

VL - 15

SP - 144

JO - Orphanet Journal of Rare Diseases

JF - Orphanet Journal of Rare Diseases

SN - 1750-1172

IS - 1

ER -

ID: 60160497